Drugs / DTaP
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT07213089 Comparator | Jul 2020 → Apr 2022 | pertussis | BioNet-Asia Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07213089 ↗ |
| Modality | Vaccine | “A single dose of Acellular pertussis (DTaP) vaccine 0.5 ml.” NCT07213089 ↗ |
| Route | Intramuscular | “A single dose of Acellular pertussis (DTaP) vaccine 0.5 ml. will be given by intramuscular as at Day 0” NCT07213089 ↗ |